Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2023-02-03 Annual Report (ESEF)
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Annual Report (ESEF) 2022
Annual Report (ESEF) Classification · 100% confidence FY 2022
2023-02-03 English
Annual Report (ESEF) 2022
Annual Report (ESEF) Classification · 100% confidence FY 2022
2023-02-03 English
Earnings Release 2022
Earnings Release Classification · 100% confidence The document is explicitly titled "Annual report 2022" and contains comprehensive financial highlights for the full year 2022, including revenue, EBITDA, EBIT, and cash flow figures, along with a forward-looking financial outlook for 2023. This content aligns perfectly with the definition of an Annual Report (10-K), which covers company activity and full financial performance for the year. Although it mentions an attached ESEF-version annual report and a webcast, the core content provided is the summary of the full annual results, making it the primary report document itself, rather than just a publication announcement (RPA). The length (5038 chars) is substantial enough to contain key report data, not just a brief announcement. FY 2022
2023-02-03 English
Annual Report 2022
Annual Report Classification · 100% confidence The document is titled 'Årsrapport 2022' (Annual Report 2022) and contains comprehensive financial statements, a management review, a letter from the Chair and CEO, and an independent auditor's report. It covers the full fiscal year 2022 and provides detailed financial performance, strategy, and governance information. It is clearly the full annual report, not an announcement or a summary. FY 2022
2023-02-03 Danish
Annual report 2022: ALK delivers sales growth of 13% with profits up 33% in 2022
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) regarding the publication of the company's 2022 Annual Report. It provides key financial highlights and explicitly mentions that the full report is 'attached' (vedhæftet) and provides links to download the files. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the Annual Report (10-K) itself.
2023-02-03 Danish
Annual report 2022: ALK delivers sales growth of 13% with profits up 33% in 2022
Annual Report Classification · 100% confidence The document is titled 'Annual report 2022' and contains comprehensive financial statements, management's review, auditor's report, and notes to the consolidated financial statements. It is clearly the full annual report for the fiscal year 2022, not an announcement or a summary. FY 2022
2023-02-03 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.